Literature DB >> 28438824

Comparison of linezolid and vancomycin lock solutions with and without heparin against biofilm-producing bacteria.

Megan K Luther1,2, Leonard A Mermel3,4, Kerry L LaPlante5,6.   

Abstract

PURPOSE: The activity of linezolid and vancomycin lock solutions against biofilm-producing strains of Staphylococcus aureus, S. epidermidis, and Enterococcus faecalis was studied.
METHODS: Two strains each of methicillin-susceptible S. aureus (MSSA), methicillin-resistant S. aureus (MRSA), and S. epidermidis, and 1 strain of vancomycin-susceptible E. faecalis and vancomycin-resistant E. faecalis were tested against vancomycin and linezolid to assess prevention of biofilm formation and eradication of these pathogens within a formed biofilm. Activity was also tested in a 72-hour in vitro central venous catheter (CVC) model. After 24 hours of biofilm growth in a CVC, a lock solution containing vancomycin (2 or 5 mg/mL) or linezolid (1 or 2 mg/mL) alone or in combination with heparin sodium (5,000 units/mL with benzyl alcohol 0.45%) was instilled and incubated at 35 °C for 72 hr. Heparin and 0.9% sodium chloride injection were also tested.
RESULTS: Linezolid and vancomycin prevented biofilm formation below the minimum inhibitory concentration for 88% and 25% of isolates tested, respectively. The addition of preservative-containing heparin decreased the activity of vancomycin and linezolid lock solutions against all strains. Vancomycin 2- and 5-mg/mL lock solutions had the most activity against MSSA and E. faecalis strains (p < 0.01). Linezolid 2 mg/mL was the most active lock solution against the MRSA strains tested (p < 0.01). There were no significant differences in vancomycin or linezolid lock solution activity against S. epidermidis.
CONCLUSION: Heparin reduced activity of vancomycin and linezolid lock solutions against S. aureus, S. epidermidis, and E. faecalis biofilms. While linezolid or vancomycin lock solution reduced overall biofilm burden, it did not completely eradicate the bacteria at tested concentrations.
Copyright © 2017 by the American Society of Health-System Pharmacists, Inc. All rights reserved.

Entities:  

Keywords:  biofilms; catheter-related infections; central venous catheters; heparin; linezolid; vancomycin

Mesh:

Substances:

Year:  2017        PMID: 28438824     DOI: 10.2146/ajhp150804

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  3 in total

1.  Clinical and Genetic Risk Factors for Biofilm-Forming Staphylococcus aureus.

Authors:  Megan K Luther; Diane M Parente; Aisling R Caffrey; Kathryn E Daffinee; Vrishali V Lopes; Emily T Martin; Kerry L LaPlante
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

2.  Pharmacokinetics, Tissue Distribution, and Efficacy of VIO-001 (Meropenem/Piperacillin/Tazobactam) for Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia in Immunocompetent Rabbits with Chronic Indwelling Vascular Catheters.

Authors:  Vidmantas Petraitis; Ruta Petraitiene; Povilas Kavaliauskas; Ethan Naing; Andrew Garcia; Christina Sutherland; Aki Yoneda Kau; Nicholas Goldner; Christopher Bulow; David P Nicolau; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2021-08-30       Impact factor: 5.191

Review 3.  Risk Factors for Infections, Antibiotic Therapy, and Its Impact on Cancer Therapy Outcomes for Patients with Solid Tumors.

Authors:  Ondřej Kubeček; Pavla Paterová; Martina Novosadová
Journal:  Life (Basel)       Date:  2021-12-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.